SB-3CT|cas:292605-14-2|西域试剂

SB-3CT,99.24%

产品编号：Bellancom-12354| CAS NO：292605-14-2| 分子式：C₁₅H₁₄O₃S₂| 分子量：306.40

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12354	￥1000.00	杭州北京（现货）
Bellancom-12354	￥1500.00	杭州北京（现货）
Bellancom-12354	￥4500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SB-3CT

产品介绍

SB-3CT 是一种有效竞争型的金属蛋白酶 MMP-2 和 MMP-9 抑制剂，K_i 值分别为 13.9 nM、600 nM。SB-3CT 对明胶酶具有高选择性。SB-3CT 可透过血脑屏障，具有神经保护和抗癌作用。

生物活性

SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with K_i values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity.

体外研究

SB-3CT has shown efficacy in an animal model of severe traumatic brain injury (TBI). SB-3CT inhibits MMP-9 with an inhibition constant K_i of 400±15 nM.
Inhibition of PC3 tumor growth by SB-3CT could also be a direct consequence of reduced extracellular matrix degradation within the bone tissue by the tumor cells themselves and/or by osteoclasts. Indeed, SB-3CT treatment is associated with a reduced osteolytic response, indicating that SB-3CT helps to preserve bone integrity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SB-3CT (i.p.; 50 mg/kg; every other day; five weeks) inhibits intraosseous growth of human PC3 cells within the marrow of human fetal femur fragments previously implanted in SCID mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old male C.B.-17.SCID mice
Dosage:	50 mg/kg
Administration:	IP; every other day; five weeks
Result:	Inhibited intraosseous growth of human PC3 cells within the marrow of human fetal femur fragments previously implanted in SCID mice.

体内研究

SB-3CT (i.p.; 50 mg/kg; every other day; five weeks) inhibits intraosseous growth of human PC3 cells within the marrow of human fetal femur fragments previously implanted in SCID mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old male C.B.-17.SCID mice
Dosage:	50 mg/kg
Administration:	IP; every other day; five weeks
Result:	Inhibited intraosseous growth of human PC3 cells within the marrow of human fetal femur fragments previously implanted in SCID mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (163.19 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2637 mL	16.3185 mL	32.6371 mL
5 mM	0.6527 mL	3.2637 mL	6.5274 mL
10 mM	0.3264 mL	1.6319 mL	3.2637 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 20% Cremophor EL 70% ddH2O
Solubility: 5 mg/mL (16.32 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (8.16 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (8.16 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.16 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.16 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。